---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-228956"
form_type: "8-K/A"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-05-18T20:20:26+00:00"
generated_at: "2026-05-18T20:21:39.759821+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quince reports positive Phase 2a LAM-001 data in PH-ILD; 6MWD +67.4m, PVR -33.9%

## Summary
- Phase 2a open-label trial in PH-ILD (n=4 evaluable) on stable treprostinil showed 6MWD increase of 67.4 meters and PVR reduction of 33.9% at 24 weeks.
- All evaluable PH-ILD patients improved from Functional Class III to II by Week 24; LAM-001 was generally well tolerated.
- Phase 2b trial in PH-ILD to begin mid-2026 with topline data expected in Q1 2028.
- 8-K/A corrects sign errors in original press release table for PVR percentages (now shown as -35.3% and -33.9% for evaluable population and PH-ILD subgroup respectively).
- LAM-001 is an inhaled mTOR inhibitor acquired from Orphai Therapeutics; Quince plans to continue development in PH-ILD.

## SEC filing metadata
- accession: 0001193125-26-228956
- form_type: 8-K/A
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-05-18T20:20:26+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526228956/0001193125-26-228956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526228956/d135388d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-228956
- JSON: https://secwatch.observer/filing/0001193125-26-228956.json
- Plain text: https://secwatch.observer/filing/0001193125-26-228956.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.